CAIX PET/CT Guided Radiation Therapy for Recurrent Clear Cell Renal Cell Carcinoma
ClinicalTrials.gov Studies
Summary
This is a prospective, single-arm clinical trial (NCT07540260) investigating CAIX-targeted PET/CT imaging combined with stereotactic ablative radiotherapy (SABR) for adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG and CAIX-targeted) to map disease sites, with PET/CT-visible lesions treated when feasible. The study plans to enroll approximately 70 participants and will evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events.
What changed
This document registers a new clinical trial on ClinicalTrials.gov. It provides a structured summary of a prospective study protocol for treating recurrent clear cell renal cell carcinoma using CAIX-targeted PET/CT imaging combined with stereotactic ablative radiotherapy as a component of standard systemic therapy.
Affected parties include clinical investigators, oncology research sites, and healthcare providers specializing in renal cell carcinoma treatment. The study's registration on ClinicalTrials.gov establishes formal documentation of the trial protocol for regulatory compliance, informed consent requirements, and adverse event reporting under applicable human subjects research frameworks.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
N/A NCT07540260 Kind: NA Apr 20, 2026
Abstract
This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites. When feasible, PET/CT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: ~70).
Conditions: Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer
Interventions: PETCT-guided radiation therapy
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.